203 related articles for article (PubMed ID: 15761940)
1. Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver.
Hong Y; Ramzan I; McLachlan AJ
J Pharm Sci; 2005 Jan; 94(1):169-76. PubMed ID: 15761940
[TBL] [Abstract][Full Text] [Related]
2. Disposition of amphotericin B in the isolated perfused rat liver.
Hong Y; Ramzan I; McLachlan AJ
J Pharm Pharmacol; 2004 Jan; 56(1):35-41. PubMed ID: 14979999
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential.
Matsui S; Imai S; Yabuki M; Komuro S
Arzneimittelforschung; 2009; 59(9):461-70. PubMed ID: 19856794
[TBL] [Abstract][Full Text] [Related]
4. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Booth CL; Brouwer KR; Brouwer KL
Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.
Ellis AG; Webster LK
Cancer Chemother Pharmacol; 1999; 43(1):13-8. PubMed ID: 9923536
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):828-33. PubMed ID: 11850268
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Andes D; Safdar N; Marchillo K; Conklin R
Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
[TBL] [Abstract][Full Text] [Related]
8. Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations.
Welte R; Eschertzhuber S; Weiler S; Leitner-Rupprich S; Aigner M; Lass-Flörl C; Stienecke E; Bellmann-Weiler R; Joannidis M; Bellmann R
Int J Antimicrob Agents; 2015 Sep; 46(3):325-31. PubMed ID: 26119497
[TBL] [Abstract][Full Text] [Related]
9. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
[TBL] [Abstract][Full Text] [Related]
10. Disposition of aerosolized liposomal amphotericin B.
Lambros MP; Bourne DW; Abbas SA; Johnson DL
J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system.
Segarra I; Movshin DA; Zarif L
J Pharm Sci; 2002 Aug; 91(8):1827-37. PubMed ID: 12115810
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent inhibition of transporter-mediated hepatic uptake and biliary excretion of methotrexate by cyclosporine A in an isolated perfused rat liver model.
Parasrampuria R; Mehvar R
J Pharm Sci; 2010 Dec; 99(12):5060-9. PubMed ID: 20821379
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
Walsh TJ; Goodman JL; Pappas P; Bekersky I; Buell DN; Roden M; Barrett J; Anaissie EJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3487-96. PubMed ID: 11709329
[TBL] [Abstract][Full Text] [Related]
14. Effects of amphotericin B on the excretory function and the colloid clearance capacity of the perfused rat liver.
Gaeta GB; Utili R; Adinolfi LE; Tripodi MF; Esposito V
J Hepatol; 1989 May; 8(3):344-50. PubMed ID: 2732448
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and disposition of the antiviral nucleoside analogue AM365 in the isolated perfused rat liver.
Wang J; Nation RL; Evans AM; Cox S; Shackleford D
Curr Drug Metab; 2005 Oct; 6(5):487-93. PubMed ID: 16248840
[TBL] [Abstract][Full Text] [Related]
17. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.
Hong Y; Shaw PJ; Tattam BN; Nath CE; Earl JW; Stephen KR; McLachlan AJ
Eur J Clin Pharmacol; 2007 Feb; 63(2):165-72. PubMed ID: 17180621
[TBL] [Abstract][Full Text] [Related]
18. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats.
Wasan KM; Vadiei K; Lopez-Berestein G; Luke DR
J Infect Dis; 1990 Mar; 161(3):562-6. PubMed ID: 2313133
[TBL] [Abstract][Full Text] [Related]
20. Effects of cyclosporine A on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver model.
Khezrian M; Sheikholeslami B; Dadashzadeh S; Lavasani H; Rouini M
Cancer Chemother Pharmacol; 2015 May; 75(5):961-8. PubMed ID: 25757960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
